New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...
| Publicado en: | Current Oncology Vol. 31; no. 5; pp. 2453 - 2481 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
MDPI
May2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=177496563&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 177496563 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 11980052 5EKK jtl: Current Oncology issn: 11980052 maglogo: N pubinfo: dt: May2024 vid: 31 iid: 5 pid: 97109 pub: MDPI artinfo: ui: 177496563 10.3390/curroncol31050184 177496563 ppf: 2453 ppct: 28 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices. aug: au: Stewart, David J. Bradford, John-Peter Sehdev, Sandeep Ramsay, Tim Navani, Vishal Rawson, Nigel S. B. Jiang, Di Maria Gotfrit, Joanna Wheatley-Price, Paul Liu, Geoffrey Kaplan, Alan Spadafora, Silvana Goodman, Shaun G. Auer, Rebecca A. C. Batist, Gerald affil: Division of Medical Oncology, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada (J.G.) sug: ab: Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We need system-wide reform that will enable less expensive, faster drug development. The speed with which COVID-19 vaccines and AIDS therapies were developed indicates this is possible if governments prioritize it. Countries also differ in how they value drugs, and generally, those willing to pay more have better, faster access. Canada is used as an example to illustrate how "incremental cost-effectiveness ratios" (ICERs) based on measures such as gains in "quality-adjusted life-years" (QALYs) may be used to determine a drug's value but are often problematic, imprecise assessments. Generally, ICER/QALY estimates inadequately consider the impact of patient crossover or long post-progression survival, therapy benefits in distinct subpopulations, positive impacts of the therapy on other healthcare or societal costs, how much governments willingly might pay for other things, etc. Furthermore, a QALY value should be higher for a lethal or uncommon disease than for a common, nonlethal disease. Compared to international comparators, Canada is particularly ineffective in initiating public funding for essential new medications. Addressing these disparities demands urgent reform. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|